Nitazoxanide and probiotics for the treatment of recurrent Clostridium difficile infection in a peritoneal dialysis patient.
Nitazoxanide has been proven to be efficacious for the treatment of Clostridium difficile infection (CDI), but data is limited in peritoneal dialysis (PD) patients. This report details the successful utilization of nitazoxanide and probiotics to treat multirecurrent CDI in a PD patient. A 58-year-old woman was admitted with hypotension, nausea and vomiting attributed to metronidazole therapy for CDI, her third CDI treatment regimen in 3 months. During her admission, the patient developed CDI and was started on a 6-week regimen of nitazoxanide and probiotics to assist in re-establishing the colonic flora. The regimen was well tolerated and the patient remained disease free at follow up, four months later.
Yangco
Bienvenido G
BG
Infectious Disease Research Institute, Advanced Care Hospitalists, Tampa, FL, USA. byangco@gmail.com
Sher
Gulab
G
Bardin
Matthew C
MC
D000977:Antiparasitic Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000302:isolation & purification; D003015:Clostridium Infections / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005767:Gastrointestinal Diseases / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008875:Middle Aged; D009574:Nitro Compounds; D010530:Peritoneal Dialysis; D019936:Probiotics / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
D000977:Antiparasitic Agents; D009574:Nitro Compounds; D013844:Thiazoles; C041747:nitazoxanide